Results of the phase I clinical trial of the investigational agent DMOT4039A has found the drug to be well tolerated in some patients and display initial evidence of anti-cancer activity among patients suffering from pancreatic and ovarian cancers, researchers told the 50th Annual Meeting of the American Society for Clinical Oncology (ASCO). The drug is in fact a combination of a chemotherapeutic agent with an antibody, technically called an antibody-drug conjugate ...
via Medindia Health News
More READ 
Lake forest health and fitness http://ift.tt/1wFzBI2
No comments:
Post a Comment